Financials
The number of medical journal reports on fibromyalgia is growing, but most of the focus is headed in the wrong direction. Patients don’t need more hyped-up studies about the marvels of exercise and behavioral therapies, they need (and deserve) more investigations that will significantly impact their care.
Fibromyalgia research must be redirected toward patient needs, such as improved treatments, objective biomarkers, and a better understanding of what causes this disease. AFSA’s small research grants program is essential for steering studies in the direction of patient-relevant projects. Although the National Institutes of Health funds research, learn why you can’t count on it for improving your care.
In 2024, AFSA funded three exciting new research projects. Then in 2025, we funded three more. See our Projects Funded section for details. And for those interested, we posted a new request for applications (RFA) to continue our research-funding mission in 2026 (see Grant Guidelines).
While the 2023 RFA trims our cash reserves by 20 percent ($215,138), we actively working to raise funds to award multiple grants each year. In the meantime, we are happy to share with you graphs of our asset balances and financial summaries for the past three years. Our fiscal year is from July 1st through June 30th, so the data for 2023 includes the funding of two of the three grant awards in 2024.
If you would like to download our IRS Form 990 for our last three fiscal years, they are available below as PDFs. In addition, our Articles of Incorporation, Bylaws, IRS Determination Letters (initial and 5-year approval), Conflict of Interest Policy, and other governing policies are available.
